藥物研發外包的全球市場 (2022-2028年):藥物類型·工作流程·治療領域·各用途的規模·佔有率·成長分析·預測

Global Drug Discovery Outsourcing Market Size, Share, Growth Analysis, By Drug Type, By Workflow, By Therapeutic area, By Application - Industry Forecast 2022-2028

出版日期: 2023年04月30日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

藥物研發外包的市場規模在2021年估算為32億6,000萬美元，2022年35億美元，在2023年到2030年的預測期間中預計將以7.3％的年複合成長率推移，到2030年達到62億美元的規模。

公共機構和私營公司之間的合作正在取得進展，加快了藥物發現過程，全球對藥物發現外包服務的需求正在增加。此外，製藥和生物製藥行業研發費用的增加、對分析測試服務的需求增加、罕見病和孤兒藥研究的舉措以及高昂的內部藥物開發成本正在為藥物發現服務市場創造新的收入來源。

本報告提供全球藥物研發外包的市場調查，彙整市場概要，市場的各種影響因素的分析，技術·革新趨勢，市場規模的轉變·預測，各種區分·各地區的明細，競爭情形，主要企業簡介等資訊。

市場概要
市場規模
市場動態
促進因素
機會
阻礙因素
課題
主要市場洞察
技術分析
價格分析
供應鏈分析
價值鏈分析
市場生態系統
IP分析
貿易分析
Start-Ups分析
原料分析
革新矩陣
開發中產品的分析
宏觀經濟指標
主要投資分析
主要成功因素
競爭的程度
市場動態及預測
市場動態
促進因素
機會
阻礙因素
課題
法規情形
波特分析
未來的阻礙相關Skyquest的特別見解
全球藥物研發外包市場:藥物各類型
- 市場概要
- 低分子
- 高分子
- 生技藥品
全球藥物研發外包市場:工作流程
- 市場概要
- 目標的鑑定·篩檢
- 目標的驗證·功能性資訊學
- 領導的特定·候補的最佳化
- 前臨床開發
- 其他
全球藥物研發外包市場:各治療領域
- 市場概要
- 呼吸系統
- 腫瘤
- 眼科
- 血液
- 心血管系統
- 內分泌
- 腸胃
- 免疫調節
- 抗感染疾病
- 中樞神經系統
- 皮膚科
- 泌尿器官系統
全球藥物研發外包市場:各用途
- 市場概要
- 醫院·診療所
- 醫療實驗室
- 其他
全球藥物研發外包市場:各地區
- 市場概要
- 北美
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他的歐洲地區
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他的亞太地區
- 南美
- 巴西
- 其他的南美地區
- 中東·非洲
- GCC各國
- 南非
- 其他的中東·非洲地區
競爭情形
前五名公司的比較
主要企業的地位
主要企業的招聘策略
主要成功策略
市場上最近的活動
主要企業的市場佔有率
主要企業簡介
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
WuXi AppTec Co., Ltd.
Albany Molecular Research Inc. (AMRI)
GVK Biosciences Private Limited
Sygnature Discovery
Pharmaron Beijing Co., Ltd
WuXi Biologics (Cayman), Inc.
Domainex Ltd.
Thermo Fisher Scientific, Inc.
Jubilant Biosys Ltd.
Evotec SE
Eurofins Discovery
GenScript Biotech Corporation

簡介目錄

Product Code: SQMIG35C2011

Global Drug Discovery Outsourcing Market size was valued at USD 3.26 billion in 2021 and is poised to grow from USD 3.5 billion in 2022 to USD 6.2 billion by 2030, growing at a CAGR of 7.3% in the forecast period (2023-2030).

Rising collaborations between public and commercial entities speed up drug discovery procedures, increasing global demand for drug discovery outsourcing services. The ultimate goal of a preclinical drug discovery programme is to deliver one or more clinical candidate molecules that have sufficient evidence of biological activity at a disease-relevant target as well as sufficient safety and drug-like properties to be tested in humans.

Growing R&D expenditure in the pharmaceutical and biopharmaceutical industries, rising demand for analytical testing services, initiatives for rare disease and orphan drug research, and the high cost of in-house drug development are all creating new revenue pockets in the drug discovery services market.

Many pharmaceutical and biotechnology businesses partnered with CROs through long-term agreements, partnerships, and collaborations around the world to accelerate the R&D process. Eurofins Scientific SE (France), for example, launched Adaptive immune response models in May 2021 to study the immunological repercussions of SARS-CoV-2 and other viral diseases for drug discovery.

Top-down and bottom-up approaches were used to estimate and validate the size of global Drug Discovery Outsourcing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Segments covered in this report

Global Drug Discovery Outsourcing Market is segmented on the basis of drug type, workflow, therapeutic area, application, and region. By drug type, the Drug Discovery Outsourcing Market is segmented into small molecule, large molecule, and biologics. By workflow, the Drug Discovery Outsourcing Market is segmented into Target Identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and others. By therapeutic area, the Drug Discovery Outsourcing Market is segmented into Respiratory system, oncology, ophthalmology, haematology, cardiovascular, endocrine, gastrointestinal, immunomodulation, anti-infective, central nervous system, dermatology, and genitourinary system. By application, the Drug Discovery Outsourcing Market is segmented into Hospitals & clinics, medical laboratories, and others. By region, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

Drivers

Increased investment in healthcare infrastructure development will create lucrative opportunities for the global drug discovery outsourcing market.

Pharmaceutical and biopharmaceutical businesses' increasing R&D expenditures are leading them to seek fully integrated or functional outsourcing services for drug research and development, from the early development stage to the late-stage development phase. Outsourcing has grown as a strategic solution to offset the shortage of in-house resources required for new product development as pharma businesses face great pressure to limit fixed costs. Large pharmaceutical corporations are shifting to a leaner business strategy that mainly relies on outsourcing. Most pharmaceutical and biopharmaceutical businesses outsource their testing services throughout R&D to increase profitability, meet drug development timeframes, and save money. This is evidenced by major pharmaceutical companies' recent deals with CROs that provide drug discovery and development services. As a result, rising pharmaceutical R&D spending fuels the growth of the drug discovery services industry.

Restraint

Stringent policies and high manufacturing costs will stymie the growth of the drug delivery outsourcing market.

The primary focus of regulatory bodies during drug approval is ensuring safety and efficacy, which significantly raises the cost of drug development and the final product. This aspect can have a substantial impact on medicine uptake in price-sensitive emerging markets. Aside from that, different legislations that protect product quality (such as GMP) frequently raise manufacturing prices. Animal testing in drug discovery is governed by strict restrictions. The most regularly employed animals in study are mice, rats, fish, amphibians, and reptiles. Concerns about the ethical use of animals in research have prompted governments to enact animal safety and use legislation, which poses various hurdles to the smooth operation of drug discovery research. Companies have been obliged to find alternative methods to reduce animal use. Novo Nordisk, for example, employs bio simulation, which entails employing computer models to imitate human biology. However, this has not been fully implemented throughout the market.

Market Trends

The escalation of cancer cases will shape the future of the global drug discovery outsourcing market.

As more small and medium-sized businesses outsource drug discovery services, the value chain of the drug discovery outsourcing market will see new growth prospects in the future years.

During the foreseeable period, oncology will lead worldwide demand since the burden of curing cancer remains a global duty.